Wednesday, April 26, 2017| Allergan, Clinical Trials, Diabetic Retinopathy, FDA Approval/Clearance, Hydrus™ Microstent, Ivantis, Technology

EyewireTV — FDA Clears TrueTear Neurostimulator; IBM Technology Detects DR

In this week’s EyewireTV, Allergan receives marketing authorization from the FDA for the TrueTear Intranasal Tear Neurostimulator, developed to temporarily increase tear production during neurostimulation in adult patients; and IBM releases the results of new research using deep learning and visual analytics technology to advance early detection of diabetic retinopathy. Also, Ivantis receives FDA clearance to initiate a second investigational device exemption clinical trial of the Hydrus Microstent.

Watch Video

Wednesday, April 19, 2017| Aberrometry, Aerie Pharmaceuticals, Clinical Trials, Diabetic macular edema, DME, Diabetic Retinopathy, Excimer Lasers, FDA Approval/Clearance, Glaucoma, Lucentis, Nidek, Ranibizumab

EyewireTV — New Lucentis Approval; Nidek Launches Excimer Laser System

In this week’s EyewireTV, Lucentis (ranibizumab) receives FDA approval for the treatment of diabetic retinopathy in people with or without diabetic macular edema; and Nidek launches the NAVEX Quest M2 Nidek Advanced Vision Excimer Laser System, which incorporates the Quest M2 excimer laser system, the OPD-Scan III aberrometer and corneal topographer, and Final Fit software. Also, Aerie Pharmaceuticals reports 6-month topline safety and efficacy results of its phase 3 clinical trial (Rocket 4) for glaucoma product candidate Rhopressa.

Watch Video

Tuesday, April 11, 2017| Bausch+Lomb, Dry Eye, FDA Approval/Clearance, Imprimis Pharmaceuticals, Phacoemulsification, Stellaris Vision Enhancement System

EyewireTV — FDA Outpaces Europe in Drug Approvals; New Phaco Platform

In this week’s EyewireTV, a study published online in the New England Journal of Medicine reveals that the FDA outpaced the European Medicines Agency in review times and approval of new drugs between 2011 and 2015; and Bausch + Lomb receives FDA 510(k) clearance for the Stellaris Elite vision enhancement system, the company’s next-generation phaco platform. Also, Imprimis Pharmaceuticals enters into a licensing agreement for the exclusive worldwide rights to Klarity, a patented ophthalmic topical solution and gel technology for patients with dry eye disease.

Watch Video

Wednesday, April 05, 2017| , Cataracts

EyewireTV - Ocular Melanoma Trial; Hepatitis C Link to Cataracts

In this week’s EyewireTV, the first cases using a new drug candidate (AU-011; Aura Biosciences) for treating ocular melanoma are performed at Wills Eye Hospital in Philadelphia; the National Eye Institute outlines its Audacious Goals Initiative, which provides recommendations for regenerating retinal ganglion cells. Also, a large population-based study suggests hepatitis C infection may increase the risk of cataracts.

Watch Video

Wednesday, March 29, 2017| AcrySof® IQ ReSTOR Multifocal IOL, Alcon, Allergan, Astigmatism, FDA Approval/Clearance, Intraocular Pressure, IOP, Presbyopia

EyewireTV — New Multifocal Toric IOL; Restasis Multidose Now Available

In this week’s EyewireTV, the FDA approves Alcon’s Acrysof ReSTOR 2.5 D Multifocal Toric IOL with Activefocus, designed to address astigmatism and presbyopia at the same time; and Allergan announces the availability of Restasis Multidose, the first and only FDA-approved preservative-free, prescription eye drop in the United States to be available in a multidose bottle. Also, the Icare HOME tonometer, which allows for 24-hour self-measuring of IOP, receives FDA clearance.

Watch Video

Wednesday, March 22, 2017| dry age-related macular degeneration, dry AMD, Glaucoma, Glaukos Corporation, Intraocular Pressure, IOP, Microinvasive Glaucoma Surgery (MIGS), Minimally Invasive Micro Sclerostomy (MIMS) , stem cell therapy

EyewireTV — Unregulated Stem Cell Procedures; New Glaucoma Device

In this week’s EyewireTV, the New England Journal of Medicine details an alarming case in which three women with dry AMD suffered severe, permanent eye damage after stem cells were injected into their eyes in an unproven treatment at a clinic in Florida; and Israel-based Sanoculis receives the CE Mark for its minimally invasive micro sclerostomy (MIMS) device for the reduction of IOP in glaucoma patients. Also, the American Medical Association grants Glaukos 5-year extensions to three Category III CPT codes that detail Medicare reimbursements for current and future microinvasive glaucoma surgery (MIGS) devices.

Watch Video

Wednesday, March 15, 2017

EyewireTV - Footage of the First SMILE Procedures; Ackman Unloads His Valeant Stock

In this week’s EyewireTV, exclusive footage of the first ReLEx SMILE procedures to be performed in the United States following the recent FDA approval; and Pershing Square Capital Management CEO Bill Ackman said that his hedge fund has sold all its shares in Valeant, the parent company of Bausch + Lomb. Also, eSight Corporation launches new electronic glasses that aim to restore up to 20/20 vision to the blind.

Watch Video

Wednesday, March 08, 2017| FDA Approval/Clearance, Glaucoma, IOL Calculations, IRIDEX, Topcon Medical Systems

EyewireTV — Republicans Aim to Replace Obamacare; Aladdin Biometer FDA Clearance

In this week’s EyewireTV, House Republicans unveil legislation called the American Health Care Act, which aims to repeal and replace the Affordable Care Act; and Topcon Medical Systems receives FDA clearance for the Aladdin Biometer with Corneal Topographer HW3.0, a device designed to save time and add accuracy to IOL calculation measurements. Also, Iridex announces the availability of the G-Probe Illuminate, a new FDA-cleared probe for use with the CYCLO G6 Glaucoma Laser System.

Watch Video

Thursday, March 02, 2017| Abbott Medical Optics, AMO, Acquisitions, Mergers, Bausch+Lomb, Carl Zeiss Meditec, FDA Approval/Clearance, Glaucoma, Johnson & Johnson Vision Care, Myopia, Nicox , ReLEx SMILE, VisuMax femtosecond laser

EyewireTV — J&J Completes AMO Acquisition; SMILE Procedure Commercially Available in US

In this week’s EyewireTV, Johnson & Johnson completes its $4.3 billion acquisition of Abbott Medical Optics. The combined company will operate under the brand name Johnson & Johnson Vision; and Carl Zeiss Meditec receives FDA approval of a PMA supplement for software changes to the VisuMax femtosecond laser, allowing surgeons in the US to perform the ReLEx SMILE procedure for the correction of myopia. Also, Bausch + Lomb and Nicox resubmit a new drug application to the FDA for glaucoma candidate latanoprostene bunod (0.024%).

Watch Video

Wednesday, February 22, 2017| Blindness, Dry Eye, Eyegate Pharmaceuticals, Inflammation, Shire, Valeant

EyewireTV — Early Xiidra Sales; Valeant Boosts Ophthalmic Portfolio

In this week’s EyewireTV, Shire releases information about the early sales of its dry eye disease drug Xiidra (lifitegrast); and Valeant acquires the global commercial and manufacturing rights to EyeGate Pharmaceuticals’ EyeGate II Delivery System and EGP-437 combination product for postoperative pain and inflammation. Also, the Himalayan Cataract Project, a major eye care initiative to develop sustainable solutions for blindness throughout Asia and Africa, is one of eight finalists in a $100 million global competition.

Watch Video

Wednesday, February 15, 2017| FDA Approval/Clearance, Lions Eye Institute , Lucentis

EyewireTV — Lucentis Launches Prefilled Syringe; LEITR Doubles in Size

In this week’s EyewireTV, Lucentis (ranibizumab) is now available in the United States in a new 0.5-mg prefilled syringe; and the Lions Eye Institute for Transplant & Research has doubled its size after acquiring International Sight Restoration, the largest eye bank for international ocular distribution. Also, three companies with early-stage products for serious ocular conditions (Aura Biosciences, Regenxbio, and GenSight Biologics) receive the green light from the FDA to proceed with clinical development.

Watch Video

Wednesday, February 08, 2017| Glaucoma

EyewireTV — World’s Top Glaucoma Specialists Discuss Future Treatment Options

In this week’s EyewireTV, leading glaucoma specialists, investors, and industry executives gather at the Glaucoma 360 meeting in San Francisco to exchange ideas and provide updates on new developments in glaucoma. Several attendees talk to EyewireTV about which technologies or treatment options—either already available or in clinical development—they believe will have a major impact on the way glaucoma patients are treated.

Watch Video

Wednesday, February 01, 2017| Alcon, Astigmatism, LENSAR Laser, Novartis, Retinal Vein Occlusion, RVO

EyewireTV — Novartis Considers Alcon Spinoff; Robot Used for RVO Surgery

In this week’s EyewireTV, Novartis executives say they are considering several options for the company's Alcon unit, including the possibility of separating from the eye care division; and Lensar announces the launch of Streamline III, an upgrade to the Lensar laser system that facilitates more precise and intuitive astigmatism management. Also, surgeons in Belgium for the first time use robotic support to safely dissolve a blood clot in a patient with retinal vein occlusion.

Watch Video

Wednesday, January 25, 2017| Dry Eye, FDA Approval/Clearance, Implantable Miniature Telescope, IMT, Intraocular lens, IOL, IOLs, Macular Degeneration, VisionCare Ophthalmic Technologies

EyewireTV — New Dextenza NDA; Dry Eye Projections

In this week’s EyewireTV, 6 months after being turned down by the FDA, Ocular Therapeutix resubmits a new drug application for Dextenza (dexamethasone insert 0.4 mg) for the treatment of ocular pain after ophthalmic surgery; and the FDA grants VisionCare approval to initiate a clinical study of its miniature telescope implant in patients with end-stage macular degeneration who were previously implanted with an IOL. Also, a new report form Market Scope projects the global dry eye treatments market to grow significantly over the next 5 years—driven by new drugs and procedures, along with better access.

Watch Video

Wednesday, January 18, 2017| Cataract, Drug Delivery, Essilor, ForSight Vision, Glaucoma, Imprimis Pharmaceuticals, Luxottica Group, Roche

EyewireTV - Blockbuster Eyewear Merger; New Imprimis Formulations

In this week’s EyewireTV, Luxottica Group, the Italian maker of Ray-Ban sunglasses, agrees to a merger with French optical lens maker Essilor International, creating a $49 billion eyewear giant; and Imprimis Pharmaceuticals introduces several new cataract and glaucoma formulations. Also, Roche acquires ForSight Vision4, providing Roche exclusive access to a proprietary eye drug delivery technology.

Watch Video
Load More